We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

HCRI Successfully Completes Randomization in the DAPT Study

HCRI Successfully Completes Randomization in the DAPT Study

HCRI Successfully Completes Randomization in the DAPT Study

HCRI Successfully Completes Randomization in the DAPT Study

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "HCRI Successfully Completes Randomization in the DAPT Study"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

The Harvard Clinical Research Institute (HCRI) has announced the successful completion of randomization in the DAPT Study, with the total number of patients randomized exceeding the upper goal set for the Study.

The DAPT Study is a four-year clinical trial investigating the duration of dual antiplatelet therapy (DAPT, the combination of aspirin and a thienopyridine/antiplatelet medication to reduce the risk of blood clots) following drug-eluting stent implantations.

The large-scale public health study is expected to bring clarity to the global medical community regarding the benefits of 12 versus 30 months of dual antiplatelet therapy in patients receiving drug-eluting stents to address coronary artery lesions.

The American College of Cardiology/ American Heart Association currently recommend 12 months of dual antiplatelet therapy for patients undergoing percutaneous coronary intervention (PCI) following placement of a drug-eluting stent.

Laura Mauri, M.D., principal investigator of the DAPT Study, an interventional cardiologist at the Brigham and Women's Hospital and Harvard Medical School in Boston, MA and chief scientific officer of Harvard Clinical Research Institute, said: “The clinical community is awaiting a definite answer as to the appropriate duration of dual antiplatelet therapy that balances beneficial long-term outcomes while minimizing bleeding complications. The DAPT Study is uniquely designed to answer this question and to draw meaningful conclusions regarding specific risks and benefits, due to its large sample size, statistical power and focus on presenting data from real-world practice. We plan to announce final results from the Study in late 2014, which we expect will inform future practice guidelines on the duration of dual antiplatelet therapy following drug-eluting stent implantation.”

Dean J. Kereiakes, M.D., co-principal investigator of the DAPT Study, medical director of The Christ Hospital Heart and Vascular Center and The Carl and Edyth Lindner Center for Research and Education at The Christ Hospital in Cincinnati, Ohio, added: “We are pleased to have successfully enrolled approximately 26,000 patients into the Study and into the participating manufacturers’ contributing studies, with approximately 12,000 total patients having been subsequently randomized. The large number of patients involved in the DAPT Study is a major strength of the trial and we are thankful to the over 450 sites throughout the United States, Canada, European Union, Australia and New Zealand that contributed to the Study.”

The DAPT Study is being conducted through a public-private collaboration involving HCRI; four major stent manufacturers: Abbott (XIENCE V®, XIENCE PRIME™), Boston Scientific Corporation (TAXUS®, PROMUS®), Cordis Corporation (CYPHER®), Medtronic, Inc. (Endeavor®); the manufacturers of thienopyridine/antiplatelet medications: Bristol-Myers Squibb Company/Sanofi Pharmaceuticals Partnership (Plavix® (clopidogrel bisulfate)) and Eli Lilly and Company and Daiichi Sankyo Company, Limited (Effient/Efient® (prasugrel)); and the U.S. Food and Drug Administration (FDA). HCRI, which is responsible for the scientific management of the DAPT Study and the independent analysis of the resulting data, received funding support from each of the drug and device manufacturers.